TIGIT与CD155在三阴性乳腺癌组织中的表达及其临床意义

目的：研究三阴性乳腺癌(TNBC)组织中T细胞免疫球蛋白和ITIM结构域蛋白(TIGIT)和CD155蛋白的表达及其与临床病理参数、生存预后的相关性，探讨两蛋白在TNBC预后中的价值。方法：收集2014年1月至2018年12月福建医科大学附属第二医院通过手术切除、术后病理检查确诊为TNBC的64例女性患者的肿瘤组织，采用免疫组化法检测TNBC组织中TIGIT、CD155的表达情况。收集入组患者的临床病理资料并随访其生存预后情况，使用卡方检验或Fisher’s精确检验分析TIGIT、CD155水平与临床病理特征的关系，通过Kaplan-Meier生存曲线、Log-Rank检验及Cox回归分析法分析TIGIT、CD155表达与预后的关系。结果：TNBC中TIGIT和CD155的阳性表达率分别为48.4%(31/64)和79.9%(51/64)。TIGIT和CD155的表达均与肿瘤大小、淋巴结转移、肿瘤分期相关(均P<0.05)，而与年龄、绝经状态、组织学分级、Ki-67均无关(均P>0.05)。生存分析结果显示，TNBC组织中TIGIT和CD155的表达均与较差的DFS相关(均...

The clinical significance of TIGIT/CD155 expression in triple negative breast cancer tissues

Objective: To investigate the expressions of T cell immunoreceptor with Ig and ITIM domain (TIGIT) and CD155 in triple negative breast cancer (TNBC) tissues and their correlations with clinicopathologic features and survival prognosis and to explore their value in the prognosis of TNBC. Methods: A total of 64 eligible female patients who underwent surgical resection and were diagnosed by pathology in the Second Affiliated Hospital of Fujian Medical University from January 2014 to December 2018were enrolled, and their tumor tissues collected. Immunohistochemistry was used to detect the expressions of TIGIT and CD155 in TNBC tissues. The clinicopathological data of the enrolled patients were collected and their survival prognosis was followed up. Chi-square test or Fisher''s exact test was used to analyze the relationship between the expressions of TIGIT and CD155 and the clinicopathological characteristics. Kaplan-Meier survival curve, Logrank test and Cox regression analysis were used to investigate the relationship between the expressions of TIGIT and CD155 and the prognosis.Results: The positive expression rates of TIGIT and CD155 in TNBC were 48.4% (31/64) and 79.9%(51/64) respectively. Both TIGIT and CD155 expressions were correlated with tumor size, lymph node metastasis and tumor stage (all P<0.05), but not with age, menstrual status,histological grade, and Ki-67 (all P>0.05). Survival analysis indicated that both TIGIT and CD155 expressions were significantly associated with poor DFS (all P<0.05), but they were not independent prognostic risk factors for TNBC. Multivariate analysis showed that only TNMstaging was an independent prognostic risk factor for TNBC patients (P<0.05). Conclusion: TIGIT and CD155 are highly expressed in TNBC and are associated with poor pathological parameters and prognosis.